Filing Flows › Companies › Protalix BioTherapeutics › Report card
Protalix BioTherapeutics earnings report card
Every report on file against what analysts and the company itself expected, and what the stock did
Beat rate2 of 4 reports beat the EPS estimate
Protalix BioTherapeutics (PLX) beat the analysts' EPS estimate in 2 of its last 4 reports (50%), by -45.5% on average. Next report: Nov 10, 2026, analysts expect EPS −$0.02.
Report by report
| Quarter | Reported | EPS est. | EPS reported | Surprise | Revenue reported |
|---|---|---|---|---|---|
| Q2 2026 | Aug 12, 2026 | −$0.01 | $0.05 | n/m | $19.9M |
| Q1 2026 | May 13, 2026 | −$0.01 | $0.22 | n/m | $33.8M |
| Q4 2025 | Mar 18, 2026 | $0.01 | −$0.07 | n/m | $9.1M |
| Q3 2025 | Nov 13, 2025 | $0.06 | $0.03 | -45.5% | $17.9M |
Estimates and reported EPS are the Street's adjusted figures. Revenue reported is from the company's filing. No daily prices are on file for these report days, so the stock's moves are not shown.
Charts
The next report: what to expect → Protalix BioTherapeutics: every quarter →
Read automatically from SEC filings, earnings releases and public estimates; errors are possible. Not investment advice.